At a glance
ClinicalIndex Comparison RecordN/ACompleted· 192 enrolled
Drug / intervention
Eyesing Redlight Instrumentother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness and Safety of Low-intensity Single-wavelength Red Light in Controlling High Myopia in Children and Adolescents：A Randomized, Controlled, Multicenter Clinical Trial
Shanghai Eye Disease Prevention and Treatment Center·interventional·Posted Jan 11, 2022·Updated Nov 18, 2023
In Brief
A clinical study evaluating Eyesing Redlight Instrument for Age 3 to 16 Years (Inclusive), Male or Female and 2 related conditions. Completed, enrolled 192 participants across 1 site.
Detailed Summary
Objective: To study the effectiveness and safety of low-intensity single wavelength red light in controlling high myopia in children and adolescents. Methods: Subject population: Children aged 3-16 years who have high myopia. Sample size: 190 subjects were planned to be enrolled and assigned to the test or control group in a 1:1 ratio.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge 3 to 16 Years (Inclusive), Male or Female, Clinical Diagnosis Confirming That Myopia Has Occurred in at Least One Eye, The Guardian Voluntarily Signed the Subject's Informed Consent Form
CountriesChina
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedJan 2022
Primary CompletionApr 2023
TodayJul 2026
First PostedJan 11, 2022
Enrollment StartFeb 4, 2021
Primary CompletionApr 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.5 years ago
Interventions
Eyesing Redlight Instrumentother
Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.